Amgen is proud to support the European Molecular Quality Network (EMQN) External Quality Assurance (EQA) scheme to help ensure high quality biomarker testing for patients with lung cancer.
In Europe, lung cancer is the main cause of cancer-related deaths; and has the lowest 5-year survival rate among other common cancers such as breast, colorectal and prostate cancer.1,2 Eighty-five percent of patients with lung cancer have non-small cell lung cancer (NSCLC), which is often diagnosed in an advanced stage and is therefore difficult to treat.3
Treatment options for lung cancer may include surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapy.4,5
Targeted therapy, which is developed against specific genetic alterations, requires biomarker testing to assess whether these alterations are present. Biomarker testing can therefore help to direct the right treatment to the right patients, also known as precision medicine.5
EMQN is a not-for-profit, community interest company which aims to raise and maintain high standards of diagnostic clinical molecular genetic testing.6
The EMQN lung scheme includes biomarker testing for EGFR, BRAF and KRAS* mutations in the context of non-small cell lung cancer.7 It aims to ensure optimal accuracy and proficiency in biomarker testing.
By participating in these schemes, laboratories gain recognition for their activities, help to drive quality improvements and innovation, and get access to support from a network of international experts. Up to 425 laboratories globally may participate in the scheme.
Supporting quality assurance for the testing of biomarkers in lung cancer demonstrates Amgen’s commitment to precision medicine.
Click here for a link to the EQA flyer to learn how laboratories can register for an EQA scheme.
*EGFR: Epidermal Growth Factor Receptor; BRAF: v-raf murine sarcoma viral oncogene homolog B1; KRAS: Kirsten rat sarcoma 2 viral oncogene homolog